Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
LLabCorp: Reimbursement Scenario a Drag Amid Other Woes
by Zacks Equity Research
On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.
ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders
by Zacks Equity Research
ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.
Myriad Genetics: Evidence Street Reviews EndoPredict Test
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.
Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.
Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the acquisition of Bremen, Germany-based software solutions developer, SCiLS GmbH.
ResMed Achieves Key Milestone in Sleep-Disordered Breathing
by Zacks Equity Research
After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.
IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Illumina Fettered With Losses: Can It Bounce Back in 2017?
by Zacks Equity Research
During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.
Masimo to Launch Advanced Monitoring Technologies in India
by Zacks Equity Research
Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3
by Zacks Equity Research
OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?
by Zacks Equity Research
On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).
Is Baxter Poised to Counter Low Cyclophosphamide Sales?
by Zacks Equity Research
On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions
by Zacks Equity Research
On Dec 27, CryoLife Inc. (CRY) was upgraded to a Zacks Rank #1 (Strong Buy).
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege
by Zacks Equity Research
Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite
by Zacks Equity Research
NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.
LabCorp: Covance Drug Prospects Bright, Competition Rife
by Zacks Equity Research
On Dec 28, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).
ResMed: SDB Business Faces Risks, Reimbursement a Drag
by Zacks Equity Research
On Dec 27, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Nutrisystem Declares Multi-Brand Marketing Approach for '17
by Zacks Equity Research
Nutrisystem Inc. (NTRI) announced that it will focus on a multi-brand marketing approach with two new distinct programs.
What's in Store for Walgreens Boots (WBA) in Q1 Earnings?
by Zacks Equity Research
Walgreens Boots Alliance, Inc (WBA) is slated to release first-quarter 2017 results, before the market opens on Jan 5.
Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger
by Zacks Equity Research
On Dec 27, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).
Align Technology Hits 52-Week High on Q3 & Dental Strength
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) scaled a new 52-week high of $102.1 on Dec 19, finally closing a bit lower at $100.3.
Align Up on Balanced Growth, Expansion of Invisalign Teen
by Zacks Equity Research
On Dec 9, 2016, we issued an updated research report on California-based Align Technology Inc. (ALGN).